Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Yoshino Kogyosho Co., Ltd.

Arte Corporation

Naoki Asakawa

Masao Nagao

Naoki Nagahara

Muneo Nonomura

Takayuki Doen

Shigeyuki Takada

Nobuo Tanaka

Yutaka Yamagata

Jun Sato

Nobuyuki Takechi

Kiyoshi Okajima

Yuki Imanishi

Yusuke Chuma

A injection-needle cover includes an injection needle enclosure portion, which has paired base-side wall portions, a cylinder portion, paired tip-end-side wall portions, an injection needle contact portion, a hook portion, and a needle tip end fixing portion. The injection needle contact portion is disposed at a position in a base-side axial space, which is a boundary between the base-side axial space and an intra-cylinder space. The injection needle contact portion has a force receiving portion and a connecting portion. The force receiving portion receives a force from the injection needle when the force receiving portion comes in contact with the injection needle. The force receiving portion has an easy sliding portion, which is disposed in an area adjacent to an injection needle, and slides more easily along the injection needle than a case where an edge slides along the injection needle.

Injection-needle cover

In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50&#xb0; C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cmor more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Method for producing granules

An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.

Injections

The present invention relates to a pharmaceutical composition containing a cycloalkene compound, a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug thereof.

Pharmaceutical composition

A process for conveniently producing a stable protein powder retaining the higher-order structure at a high level which comprises freezing a protein-containing solution at a cooling rate of about &minus;300 to &minus;10&deg; C./min. and then drying.

Proces for producing protein powder

Growing community of inventors

Takatsuki, Japan

Naoki Asakawa